Valuation: Vaxcyte, Inc.

Capitalization 4.24B 3.68B 3.46B 3.15B 5.82B 367B 6.56B 41.03B 15.7B 168B 15.91B 15.57B 618B P/E ratio 2025 *
-6.82x
P/E ratio 2026 * -6.33x
Enterprise value 4.24B 3.68B 3.46B 3.15B 5.82B 367B 6.56B 41.03B 15.7B 168B 15.91B 15.57B 618B EV / Sales 2025 *
-
EV / Sales 2026 * 170x
Free-Float
97.87%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-1.59%
1 week-4.89%
Current month+1.17%
1 month-10.12%
3 months-55.86%
6 months-62.01%
Current year-59.85%
More quotes
1 week 32.54
Extreme 32.54
34.94
1 month 31.07
Extreme 31.07
38.39
Current year 27.66
Extreme 27.66
93.77
1 year 27.66
Extreme 27.66
121.06
3 years 19.36
Extreme 19.365
121.06
5 years 15.51
Extreme 15.51
121.06
10 years 15.51
Extreme 15.51
121.06
More quotes
Manager TitleAgeSince
Corporate Officer/Principal 61 2013-05-26
Chief Executive Officer 57 2013-10-31
Director of Finance/CFO 55 2020-04-30
Director TitleAgeSince
Director/Board Member 57 2013-10-31
Director/Board Member 57 2018-04-30
Director/Board Member 55 2020-03-31
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-1.59%-4.89%-54.82%+62.80% 4.24B
-0.75%-3.69%-51.19%-12.26% 53.86B
-0.44%-6.27%+31.34%+44.60% 33.16B
+0.52%-4.39%+58.85%-33.33% 26.05B
+2.04%-0.04%+24.05%-14.87% 26.23B
+3.24%+4.00%+58.68%+452.64% 19.5B
+1.98%+3.94%+163.59%+1,997.75% 15.27B
-1.78%-7.02%-23.37%-31.97% 13.11B
0.00%-13.93%+105.63%-64.40% 12.49B
-0.91%-2.93%+85.78%+117.51% 11.01B
Average +0.34%-3.55%+39.85%+251.85% 21.49B
Weighted average by Cap. +0.58%-3.30%+27.05%+182.52%
See all sector performances

Financials

2025 *2026 *
Net sales - 25M 21.68M 20.43M 18.56M 34.34M 2.17B 38.69M 242M 92.57M 992M 93.81M 91.81M 3.65B
Net income -658M -571M -538M -489M -904M -57.01B -1.02B -6.37B -2.44B -26.11B -2.47B -2.42B -96B -738M -640M -603M -548M -1.01B -63.94B -1.14B -7.14B -2.73B -29.29B -2.77B -2.71B -108B
Net Debt - -
More financial data * Estimated data
Logo Vaxcyte, Inc.
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.
Employees
414
More about the company
Date Price Change Volume
25-06-20 32.87 $ -1.59% 2,520,873
25-06-18 33.40 $ -0.71% 892,461
25-06-17 33.64 $ -2.01% 899,044
25-06-16 34.33 $ -0.67% 1,026,102
25-06-13 34.56 $ +0.29% 1,208,351

Delayed Quote Nasdaq, June 20, 2025 at 04:00 pm EDT

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
32.87USD
Average target price
125.75USD
Spread / Average Target
+282.57%
Consensus

Quarterly revenue - Rate of surprise